Announcements
- Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
- Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
- Assembly Biosciences Announces Effective Date of Reverse Stock Split
- Assembly Biosciences Provides Anticipated Development Milestones for 2024
- Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®
- Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates
- Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
- Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
- Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
More ▼
Key statistics
On Thursday, Assembly Biosciences Inc (V7B:BER) closed at 13.60, 89.52% above the 52 week low of 7.18 set on Nov 22, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 13.55 |
---|---|
High | 13.85 |
Low | 13.40 |
Bid | -- |
Offer | -- |
Previous close | 13.60 |
Average volume | 1.57k |
---|---|
Shares outstanding | 5.51m |
Free float | 3.69m |
P/E (TTM) | -- |
Market cap | 81.16m USD |
EPS (TTM) | -11.22 USD |
Data delayed at least 15 minutes, as of May 16 2024.
More ▼